References
- Kang MJ, Yi SY. Nevus-like appearance of primary malignant melanoma of the esophagus. Gastroenterol Res Pract 2009;2009:285753.
- Li B, Lei W, Shao K, Zhang C, Chen Z, Shi S, Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res 2007;17:239–42.
- Volpin E, Sauvanet A, Couvelard A, Belghiti J. Primary malignant melanoma of the esophagus: a case report and review of the literature. Dis Esophagus 2002;15:244–9.
- Oshiro T, Shimoji H, Matsuura F, Uchima N, Kinjo F, Nakayama T, Primary malignant melanoma of the esophagus arising from a melanotic lesion: report of a case. Surg Today 2007;37:671–5.
- Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360–72.
- Ye CP, Qiu CZ, Huang ZX, Su QC, Zhuang W, Wu RL, Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007;13:6264–8.
- Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076–81.
- Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007;67:8014–21.